Churg-Strauss Syndrome
Churg-Strauss syndrome (CSS) is a rare autoimmune disease characterized by blood vessel inflammation (vasculitis) and eosinophilic infiltration in various organs. At our company, we are committed to advancing research and development in the field of CSS, including diagnostics and therapy development.
Introduction to Churg-Strauss Syndrome
Churg-Strauss syndrome (CSS), also known as eosinophilic granulomatosis with polyangiitis (EGPA), is a systemic vasculitis that primarily affects blood vessels in the small-to-medium size range. It is characterized by the infiltration of eosinophils, a specific type of white blood cell, into multiple organs, including the lungs, skin, heart, and nervous system. CSS typically manifests in individuals with a history of asthma or allergic rhinitis and is often accompanied by elevated eosinophil levels in the bloodstream. The development of Churg-Strauss syndrome (CSS) is believed to arise from immune system dysregulation, triggering the activation of eosinophils and subsequent tissue damage.
Fig.1 Microscopic findings of (A) multiple granuloma, (B) granuloma with fibrinoid necrosis, and (C) severe eosinophilic infiltration. (Abbasi F., et al., 2023)
Drug Discovery and Development for Churg-Strauss Syndrome
The therapeutic approach for Churg-Strauss syndrome aims to manage inflammation, suppress the immune response, and preserve organ function. Cyclophosphamide, a cytotoxic agent, has demonstrated effectiveness in controlling severe CSS cases with poor prognosis factors. However, considering its potential side effects, alternative therapies such as rituximab, a monoclonal antibody that antagonizes B cells, have been explored. Rituximab has shown promising results in inducing remission and normalizing eosinophil counts in refractory CSS cases.
Our company offers a comprehensive therapy development platform that caters to all your needs in developing therapeutics for Churg-Strauss syndrome. If you are interested in our therapy development services, please click on the link below.
Our Services
At our company, we offer a range of services to support the development of diagnostics and therapies for Churg-Strauss syndrome. Our expertise in the field allows us to provide comprehensive solutions tailored to the specific needs of our clients. Employing a comprehensive approach that includes both in vitro and in vivo studies, we thoroughly assess the effectiveness and safety of these compounds.
- Genetic Engineering Model Development
By analyzing the genetic profiles of Churg-Strauss syndrome (CSS), we can identify crucial genetic loci, such as HLA-DQ, BCL2L11, and TSLP, that exhibit significant associations with the development of CSS. Leveraging advanced gene editing technologies, we have the capability to introduce gene mutations or deletions that accurately replicate the observed genetic alterations in CSS. - Vasculitis Induction Model Development
Vasculitis, the hallmark of CSS, can be induced in animal models to study the vascular component of the disease. Our company employs various techniques to elicit vasculitis, including immune complex deposition, ANCA administration, or genetic manipulation to enhance susceptibility to vasculitis.
- Cell-Based Model Development
Churg-Strauss syndrome (CSS) involves complex interactions between different cell types, including eosinophils, endothelial cells, and immune cells. Our company offers co-culture models that recreate these cellular interactions in vitro. By combining different cell types relevant to CSS, we can study the cross-talk and signaling between cells, mimicking the inflammatory microenvironment seen in the disease. - Organoid Model Development
Organ-on-a-chip technology is an emerging field that offers a more physiologically relevant approach to studying diseases like CSS. Our company utilizes this cutting-edge technology to develop organ-on-a-chip models that mimic the microarchitecture, cellular composition, and physiological functions of specific organs affected by CSS, such as the lungs or blood vessels.
Our Advantages
Time-saving services with high efficiency
Fast and cost-efficient workflow
Timely project reporting and after-sales service
Professional and experienced multidisciplinary experts
Careful design and transparent operation process
Superior data quality and fast turnaround
Our company offers comprehensive preclinical research services for CSS, providing a platform for the evaluation of potential therapies. In addition to the services and models listed above, we also provide customized services and disease model development services to meet your specific needs. If you are interested in our services, please don't hesitate to contact us.
Reference
- Abbasi F., et al. "Cardiac Mass and Cerebrovascular Accident as Primary Manifestations of Churg-Strauss Syndrome." Archives of Iranian Medicine 26.11 (2023): 662.